Oncimmune Holdings PLC Board Appointment (1640M)
11 October 2016 - 5:00PM
UK Regulatory
TIDMONC
RNS Number : 1640M
Oncimmune Holdings PLC
11 October 2016
11 October 2016
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Appointment of Carsten Schroeder as Non-Executive Director
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer
detection company developing and commercialising its proprietary
EarlyCDT(R) platform technology, announces the appointment of
Carsten Schroeder to the Company's Board as Non-Executive
Director.
Carsten has over 20 years of senior leadership experience in the
medical diagnostics sector. Since 2014 he has been President of the
Diagnostic Division at Grifols, S.A. where he is responsible for
global commercial operations and overall strategy, including
leading its growth and innovation in Transfusion Medicine and
Specialty Diagnostics.
Prior to that, and before its acquisition by Grifols, Carsten
was President of Novartis Diagnostics. Carsten joined Novartis
Diagnostics in 2010 as Vice President of Commercial Operations for
the EMEA region where he oversaw expansion into new markets. During
his time at Novartis he was a member of the Vaccines &
Diagnostic Division Executive Committee and served as Site Head for
its Emeryville campus in California. Carsten has also held
executive positions with Boston Scientific, Mallinckrodt (now
Covidien) and Boehringer Ingelheim.
Mr. Schroeder holds an MBA from the European School of
Management in Paris (ESCP) and a Bachelor of Arts in Economics from
the University of Cologne in Germany.
Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: "I am
very pleased to announce the appointment of Carsten and welcome him
to the Board. His successful track record of launching new products
globally will be invaluable to Oncimmune as we continue to expand
across the US, Europe and into Asia."
Commenting on his appointment, Carsten Schroeder said:
"Oncimmune's EarlyCDT(R) platform technology, which can detect
cancer up to four years earlier than other methods, could transform
current methods of cancer detection and save the lives of patients.
The opportunity to join the Board of Oncimmune was extremely
appealing and I look forward to working with Geoffrey and the
team."
The following information is disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
- Full name and age: Carsten Schroeder, 50
- Current Directorships: Progenika Biopharma s.l., AdvaMedDX,
California Life Science Association, National Blood Foundation
- Past Directorships (within the previous 5 years): None
No further information in connection with his appointment is
required to be disclosed under Schedule Two, paragraph (g) of the
Aim Rules for Companies.
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Broker)
Phil Walker, Giles Balleny, Dominic Wilson
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey
Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
About Oncimmune
Oncimmune is a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT(R) platform
technology. Oncimmune has pioneered the development of autoantibody
tests that can detect cancer up to four years earlier than other
methods and can be applied to a very wide range of solid tumour
types. The Company's first product, EarlyCDT(R)-Lung, was launched
in 2012, as a CLIA test in the USA and since then over 145,000
commercial tests have been sold. EarlyCDT(R)-Lung is available
through physicians in the US and also privately in the UK and other
regions. EarlyCDT(R)-Lung is being used in the largest ever
randomised trial for the early detection of lung cancer using
biomarkers, the National Health Service (NHS) Scotland ECLS study
of 12,000 high-risk smokers. EarlyCDT(R) tests for liver and
ovarian cancer are in development.
Oncimmune, headquartered in Nottingham, United Kingdom with
testing facilities in the US, joined AIM in May 2016 under the
ticker ONC.L. For more information visit www.oncimmune.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFMMMGVGMGVZM
(END) Dow Jones Newswires
October 11, 2016 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2024 to May 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From May 2023 to May 2024